CAS
NTLA icon

Coppell Advisory Solutions’s Intellia Therapeutics NTLA Stock Holding History

Coppell Advisory Solutions’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
+134
New +$1.88K 0.04% 318
2025
Q1 		– Sell
-11,591
Closed -$132K – 1335
2024
Q4 		$132K Buy
+11,591
New +$181K 0.02% 362

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Coppell Advisory Solutions's NTLA Position: Q2 2026 in Review

Coppell Advisory Solutions opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 134 shares worth $438K. The stake represents 0.04% of the portfolio and ranks #318 among its holdings. This is a return to the name: Coppell Advisory Solutions previously reported a position in NTLA as recently as Q4 2024.

Coppell Advisory Solutions first reported a position in NTLA in Q4 2024 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Coppell Advisory Solutions held 134 shares of Intellia Therapeutics worth $438K as of Q2 2026.
  • Intellia Therapeutics was a new Coppell Advisory Solutions position in Q2 2026.
  • Intellia Therapeutics made up 0.04% of Coppell Advisory Solutions's portfolio in Q2 2026, its #318 holding.
  • Coppell Advisory Solutions first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.